Results 21 to 30 of about 20,764 (191)

Resistance patterns selected by nevirapine vs. efavirenz in HIV-infected patients failing first-line antiretroviral treatment: a bayesian analysis. [PDF]

PLoS ONE, 2011
WHO recommends starting therapy with a non-nucleoside reverse transcriptase inhibitor (NNRTI) and two nucleoside reverse transcriptase inhibitors (NRTIs), i.e. nevirapine or efavirenz, with lamivudine or emtricitabine, plus zidovudine or tenofovir.
Nicole Ngo-Giang-Huong, Gonzague Jourdain, Billy Amzal, Pensiriwan Sang-a-gad, Rittha Lertkoonalak, Naree Eiamsirikit, Somboon Tansuphasawasdikul, Yuwadee Buranawanitchakorn, Naruepon Yutthakasemsunt, Sripetcharat Mekviwattanawong, Kenneth McIntosh, Marc Lallemant, Program for HIV Prevention and Treatment (PHPT) study group   +12 more
doaj   +1 more source

Revisiting efavirenz in the era of dolutegravir: Low-dose efavirenz, a viable alternative capable of holding its own against dolutegravir-based regimens

Current Medicine Research and Practice, 2023
Background: First-line dual NRTI + NNRTI-based ART has shown good virological effectiveness; however, toxicity is common and is often the most common reason for modification of first-line ART.
Sumit Arora, Kuldeep K Ashta, Anirudh Anilkumar, Nishant Raman   +3 more
doaj   +1 more source

Sub-therapeutic nevirapine concentration during antiretroviral treatment initiation among children living with HIV: Implications for therapeutic drug monitoring. [PDF]

PLoS ONE, 2017
Nevirapine, a component of antiretroviral therapy (ART) in resource-limited settings, known for auto-induction of metabolism, is initiated at half therapeutic dose until day 14 ('lead-in period'), and subsequently escalated to full dose. However, studies
Bindu Parachalil Gopalan, Kayur Mehta, Reena R D'souza, Niharika Rajnala, Hemanth Kumar A K, Geetha Ramachandran, Anita Shet   +6 more
doaj   +1 more source

Response to antiretroviral therapy after a single, peripartum dose of nevirapine. [PDF]

, 2007
BACKGROUND: A single dose of nevirapine during labor reduces perinatal transmission of human immunodeficiency virus type 1 (HIV-1) but often leads to viral nevirapine resistance mutations in mothers and infants.
van Widenfelt, Erik, Smeaton, Laura M, Chand, Fatima, Lagakos, Stephen, Shapiro, Roger L, Stevens, Lisa, Novitsky, Vladimir, Wester, Carolyn, Arimi, Peter, Ndase, Patrick, Makhema, Joseph, Asmelash, Aida, Mazhani, Loeto, Lockman, Shahin, Thior, Ibou, Moffat, Claire, Essex, Max   +16 more
core   +1 more source

Nevirapine in HIV maintenance therapy – can “old drugs” survive in current HIV management?

Swiss Medical Weekly, 2019
AIMS OF THE STUDY Nevirapine has an exceptional record for long-term tolerability with few side effects in human immunodeficiency virus (HIV) combined antiretroviral therapy (cART). Owing to relatively frequent hypersensitivity reactions (HSR)
Julia Notter, Andrea Bregenzer, Pietro Vernazza, Christian R. Kahlert   +3 more
doaj   +1 more source

Comparison of nevirapine plasma concentrations between lead-in and steady-state periods in Chinese HIV-infected patients.

PLoS ONE, 2013
ObjectivesTo investigate the potential of nevirapine 200 mg once-daily regimen and evaluate the influence of patient characteristics on nevirapine concentrations.MethodsThis was a prospective, multicentre cohort study with 532 HIV-infected patients ...
Huijuan Kou, Xiaoli Du, Yanling Li, Jing Xie, Zhifeng Qiu, Min Ye, Qiang Fu, Yang Han, Zhu Zhu, Taisheng Li   +9 more
doaj   +1 more source

Clinical perspectives on human genetic screening to prevent nevirapine toxicity [PDF]

, 2018
Nevirapine is one of the most extensively prescribed antiretroviral drugs worldwide. However, a concern is increased risk for severe toxicity when antiretroviral-naive individuals with higher CD4 T-cell counts initiate nevirapine-containing regimens ...
Mootsikapun, Piroon, Podzamczer Palter, Daniel, Ruxrungtham, Kiat, Nevirapine Toxicogenomics Study Team, Haas, David W.   +4 more
core   +1 more source

Rejoinder to Commentaries on "A Perspective on the Appropriate Implementation of ICH E9(R1) Addendum Strategies for Handling Intercurrent Events". [PDF]

Stat Med
Statistics in Medicine, Volume 45, Issue 15-17, July 2026.
Fleming TR, Carroll KJ, Wittes JT, Emerson SS, Rothmann MD, Collins S, Levin G.   +6 more
europepmc   +2 more sources

Nevirapine versus Efavirenz for patients co-infected with HIV and Tuberculosis: A Randomised Non-Inferiority Trial [PDF]

, 2013
BACKGROUND: In countries with a high incidence of HIV and tuberculosis co-infection, nevirapine and efavirenz are widely used as antiretroviral therapy but both interact with antituberculosis drugs. We aimed to compare efficacy and safety of a nevirapine-
Nilesh Bhatt, Rui Bastos, Maryline Bonnet, Jani, Ilesh, Elizabete Nunes, Sobry, Agnès, Ilesh Jani, Baudin, Elisabeth, Silva, Carlota, Michon, Christophe, Bastos, Rui, Christophe Michon, Calmy, Alexandra, Carlota Silva, Nunes, Elizabete, Agnès Sobry, Bonnet, Maryline, Alexandra Calmy, Taburet, Anne-Marie, Bhatt, Nilesh, Rouzioux, Christine, Laura Ciaffi, Elisabeth Baudin, Ciaffi, Laura, Anne-Marie Taburet, Christine Rouzioux   +25 more
core   +1 more source

Nevirapine-associated early hepatotoxicity: incidence, risk factors, and associated mortality in a primary care ART programme in South Africa. [PDF]

, 2010
BACKGROUND: The majority of antiretroviral treatment programmes in sub-Saharan Africa are scaling up antiretroviral treatment using a fixed dose first-line antiretroviral regimen containing stavudine, lamivudine, and nevirapine.
Gilles Van Cutsem, Chu Kathryn M., Van Cutsem Gilles, Asselman Valerie, Goemaere Eric, Asselman, Valerie, Van Cutsem, Gilles, Valerie Asselman, Ford Nathan, Boulle Andrew M., Ford, Nathan, Andrew M Boulle, Goemaere, Eric, Nathan Ford, Chu, Kathryn M, Boulle, Andrew M, Kathryn M Chu, Eric Goemaere   +17 more
core   +1 more source